digital phenotyping
Semaglutide vs Tirzepatide Lean-Mass Secret Exposed?
In a 2-year digital phenotyping study, tirzepatide patients lost 2.5% more lean mass than semaglutide patients, indicating a notable difference in muscle preservation. Clinicians should weigh this when selecting therapy, especially for patients at risk of sarcopenia. Medical Disclaimer: This article is for informational purposes only and does not